From: TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy
Intervention (mAb) | Primary target | Study | Conditions | Clinical trial | Identifier |
---|---|---|---|---|---|
Bavituximab Temozolomide Radiation | PS DNA (alkylating agent) DNA (damaging energy) | Bavituximab with radiation in diagnosed glioblastoma | Glioblastoma | Phase 2 – not recruiting | NCT03139916 |
Bavituximab Pembrolizumab | PS PD-1 | Patients with advanced hepatocellular carcinoma | Hepatocellular cancer | Phase 2 - recruiting | NCT03519997 |
Bavituximab Pembrolizumab | PS PD-1 | Advanced Gastric Cancer after one prior standard therapy regimen | Gastric Cancer Gastro-Esophageal Cancer | Phase 2 - recruiting | NCT04099641 |